# Evalve

Evalve is an Asset Manager based in Menlo Park, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Menlo Park, United States
- **Region:** North America
- **Address:** Menlo Park, CA, United States
- **Founded:** 1999
- **Assets under management:** Undisclosed
- **Website:** evalve.com

## Regulatory record

- **Reports private funds:** No

## About

Evalve, a company based in Menlo Park, United States, was founded in 1999. It designs, develops, manufactures, and markets devices for repairing cardiac valves. Evalve has secured $110.9 million in total funding.

## Sectors

- Medical Devices

## People

- Ferolyn Powell — Co-founder, Former CEO
- Frederick St. Goar — Co-founder
- Dan Wallace — Former CEO

## Questions

### What became of Evalve after the Abbott acquisition?

Abbott Laboratories acquired Evalve in 2009 and integrated MitraClip into its structural heart portfolio. The device became a flagship product for Abbott's vascular division, receiving expanded FDA indications for functional mitral regurgitation in 2019 and surpassing $1 billion in annual sales within the structural heart segment. The core MitraClip technology continues to be sold globally under Abbott.

### Who were the key people behind Evalve's founding?

Evalve was co-founded by cardiologist Dr. Frederick St. Goar, who practiced at the Cardiovascular Medicine & Coronary Interventions practice in Redwood City, and Ferolyn Powell, who served as CEO and chairman. Powell had previously held leadership roles at Guidant and was a prominent figure in medtech entrepreneurship. The company drew early scientific guidance from Stanford interventional cardiology researchers.

### What was the clinical trial that supported MitraClip's approval?

The EVEREST trial (Endovascular Valve Edge-to-Edge Repair Study) was Evalve's pivotal clinical program. The study enrolled patients with moderate-to-severe or severe degenerative mitral regurgitation across dozens of U.S. and international sites, comparing the MitraClip procedure's safety and efficacy against surgical benchmarks. EVEREST II data ultimately supported CE Marking in 2008 and provided the clinical basis for the FDA submission.

### Which venture capital firms backed Evalve?

Evalve attracted early investment from Three Arch Partners, New Enterprise Associates, and other life-science-focused venture firms. The company raised multiple rounds of private financing before its acquisition, with Three Arch Partner's Mark Wan serving on the board. The precise capital structure was never publicly disclosed in full detail.

### Is the MitraClip technology still owned by the original entity?

No. Abbott Laboratories owns all MitraClip intellectual property and manufacturing through the 2009 acquisition. No independent Evalve entity remains. Abbott's disclosure materials refer to MitraClip as an internally developed and advanced product line within its structural heart segment.

## Related profiles

- [Merlin International](https://altss.com/profile/merlin-international)
- [SFA](https://altss.com/profile/sfa)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/evalve

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology